Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392676 | 0.82 | CYP2A6 (0.61) | CYP2A6CYP11B1CYP11B2PTK2PGR | |
| SCHEMBL3563871 | 0.79 | MCL1 (0.44) | CYP2A6MAP4K4CYP11B1CYP11B2KDM1A | |
| SCHEMBL5110764 | 0.79 | CYP2A6 (0.52) | CYP2A6CYP11B1CYP11B2EGFRPTK2 | |
| SCHEMBL3346102 | 0.79 | CYP2A6 (0.52) | CYP2A6CYP11B1CYP11B2PTK2PGR | |
| SCHEMBL3374955 | 0.79 | CYP2A6 (0.52) | CYP2A6CYP11B1CYP11B2PTK2PGR | |
| SCHEMBL425957 | 0.79 | CYP11B1 (0.57) | CYP2A6CYP11B1CYP11B2EGFRPTK2 | |
| SCHEMBL4901239 | 0.79 | CYP2A6 (0.47) | CYP2A6CYP11B1CYP11B2PTK2PGR | |
| SCHEMBL5293 | 0.79 | CYP2A6 (0.47) | CYP2A6MAP4K4CYP11B1CYP11B2 | |
| SCHEMBL5050 | 0.78 | CYP2A6 (0.55) | CYP2A6CYP11B1CYP11B2MKNK1MKNK2 | |
| SCHEMBL5115735 | 0.78 | CYP2A6 (0.60) | CYP2A6CYP11B1CYP11B2EGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442694-B2 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1551843-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| WO-2004024729-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | CYP2A6 240/4885MAP4K4 3063/4885CYP11B1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.